Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Regeneron Pharmaceuticals is a leader in the production of monoclonal antibodies and a wide range of other key products for the treatment of cancer, rheumatoid arthritis and hypercholesterolemia, and more.

The company's milestones:

- In 1988: The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos.

- In 1989: George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron.

- In 1990: First research paper published, becoming the most cited neurobiology paper of the year.

- In 1991: REGN stock began trading publicly on the NASDAQ.

- In 1993: First drug manufacturing facility opened in Rensselaer, NY.

- In 2000: The company's experimental drug rilonacept began clinical exploration.

- In 2003: Introduce the world to the company's proprietary Veloci technology for the first time through the VelociGene article.

- In 2006: Sarilumab, our first fully human antibody, enters clinical development.

- In 2008:The FDA approves company's first medicine, ARCALYST (rilonacept) Injection.

- In 2010: BioBus, a mobile laboratory, is launched.

- In 2012: Sanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than its competitors.

- In 2013: European business office opens in Dublin, Ireland.

- In 2014: The Regeneron Genetics Center, a new human genetics initiative, officially launches.

- In 2019: Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education. 

- In 2020: Regeneron discovers and develops novel COVID-19 antibody cocktail in record time; FDA authorizes for emergency use.

- In 2022: Regeneron takes full ownership of Libtayo® (cemiplimab) injection.

According to en.wikipedia.org, regeneron.com